

## A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes - one prior line of therapy is permitted - normal cardiac and pulmonary function - participants with partners of childbearing potential must be willing to use at least two forms of effective birth control - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion & exclusion criteria

---

**Exclusion Criteria:**

- women who are pregnant or breastfeeding - other types of pancreatic cancer - history of human immunodeficiency virus (HIV) infection - history of or active acute or chronic active hepatitis B or C infection - taking 10mg/day or more of prednisone for more than one week

### Conditions & Interventions

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), Adenocarcinoma of Pancreas, Pancreatic Cancer

### More Information

**Description:** This is an early study of a new drug, RGDCRAdCOX2F, as a single tumor injection in persons with adenocarcinoma of the pancreas. The main goal of the study is to find a safe dose of the study drug.

**Study Contact:** Edward Greeno - [green048@umn.edu](mailto:green048@umn.edu)

**Principal Investigator:** Edward Greeno, M.D.

**Phase:** PHASE1

**IRB**

**Number:** STUDY00021119

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.